Thyrocare to Sell Entire Stake in Nueclear Healthcare for ₹141.4 Crore
Thyrocare will sell its entire stake in subsidiary Nueclear Healthcare (NHL) to Trovera for ₹141.40 crore. The deal includes ₹59.50 crore in preference shares and ₹81.90 crore in cash. Thyrocare will also buy back properties from NHL for ₹20.59 crore. The sale is expected to complete by November 30, 2026, subject to shareholder approval.
The sale of a material wholly-owned subsidiary and the consequent restructuring of business focus represent a significant strategic shift for the company, impacting its future operations and financial performance.
The divestment of the radiology business allows the company to focus on its core pathology business, which is a strategic positive move. The sale consideration and the acquisition of key properties ensure continued operational capacity.
Thyrocare Technologies Limited announced that its Board of Directors has approved the sale of its entire shareholding in its wholly-owned subsidiary, Nuelear Healthcare Limited (NHL), to Trovera Healthcare Private Limited. This divestment is part of a strategic decision to exit the radiology business operated through NHL and to focus capital and management attention on its core pathology business.
The sale includes 1,11,11,000 equity shares representing 100% of NHL's paid-up capital. The aggregate consideration for this transaction is approximately ₹141.40 crore. This consideration will comprise 42,500 Compulsorily Convertible Preference Shares (CCPS) of Trovera, valued at ₹59.50 crore, and a cash component of approximately ₹81.90 crore, subject to working capital adjustments.
Concurrently, Thyrocare will acquire these 42,500 CCPS of Trovera as part of the sale consideration. Additionally, to secure continued ownership of operating premises, Thyrocare will purchase immovable properties (land and buildings) located in Gurugram and Hyderabad from NHL for an aggregate consideration of ₹20.59 crore. This purchase is intended to be completed prior to or simultaneously with the sale of NHL.
The proposed transactions are subject to shareholder approval and other applicable statutory and regulatory requirements. The sale of NHL is expected to be completed by November 30, 2026. NHL's turnover for the financial year ended March 31, 2026, was ₹44.62 crore, representing 5.38% of Thyrocare's consolidated turnover.
What to do with a filing like this
Thyrocare Technologies Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Thyrocare Technologies Limited. Read the original for the full detail.